| OAA0405 | Temsavir treatment of HIV-1-infected cells decreases envelope glycoproteins recognition by broadly-neutralizing antibodies | Oral abstract session with live Q&A | Immunotherapy (including broadly neutralizing antibodies) |
| PELBA02 | First-in-human evaluation of safety and pharmacokinetics of intravenous or subcutaneous infusions of PGT121.141.LS, an anti-V3 HIV-1 broadly neutralizing antibody in healthy volunteers without HIV | Poster exhibition | Immunotherapy (including broadly neutralizing antibodies) |
| PEMOA26 | Developing a novel HIV cure strategy: retargeting potent cytotoxic T cells to kill HIV-infected cells | Poster exhibition | Immunotherapy (including broadly neutralizing antibodies) |
| PEMOA27 | Clinical and immunometabolic patterns determining efficacy of DC-treatment reinvigorating HIV-1-specific CD8+ T cells in PLWH | Poster exhibition | Immunotherapy (including broadly neutralizing antibodies) |
| PEMOA28 | Pharmacologic intervention to reduce chronic inflammation in people with HIV | Poster exhibition | Immunotherapy (including broadly neutralizing antibodies) |
| EPA084 | Effects of COVID-19 on the cytokine background in chronic controlled HIV infection | E-poster | Immune responses to SARS-Cov2 |
| EPA085 | Vitamin D supplementation enhances cytotoxic response in patients with severe COVID-19 | E-poster | Immune responses to SARS-Cov2 |
| PEMOA30 | Persistent AP-1-induced immune activation during early SARS-CoV-2 infection revealed by simultaneous single-cell epigenetic and gene expression profiling | Poster exhibition | Immune responses to SARS-Cov2 |
| PEMOA31 | HIV skews the B cell response to SARS-CoV-2 toward extrafollicular maturation | Poster exhibition | Immune responses to SARS-Cov2 |
| PEMOA32 | The impact of delta and omicron variants in the T-cell response to mRNA vaccination in people living with HIV | Poster exhibition | Immune responses to SARS-Cov2 |